| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥15.0B | ¥14.8B | +1.8% |
| Operating Income | ¥-0.6B | ¥-0.4B | +148.4% |
| Ordinary Income | ¥-3.8B | ¥-0.4B | -457.7% |
| Net Income | ¥-4.8B | ¥-0.4B | -1168.4% |
| ROE | -6.6% | -0.5% | - |
FY2025 Q3 cumulative results show revenue of 15.0B yen (YoY +1.8%), operating loss of 0.6B yen (prior period loss 0.4B yen, deterioration of 48.4%), ordinary loss of 3.8B yen (prior period loss 0.4B yen, YoY -457.7%), and net loss of 4.8B yen (prior period loss 0.4B yen, YoY -1168.4%). While revenue achieved modest growth, profitability deteriorated significantly across all levels. Basic EPS declined to -53.32 yen from -4.23 yen in the prior year. Despite operating losses expanding modestly, the substantial widening of ordinary and net losses was primarily driven by non-operating factors, particularly equity method losses of 3.1B yen and extraordinary losses of 1.0B yen. The company maintains a strong financial position with equity ratio of 91.1% and cash reserves of 25.7B yen, providing financial cushion despite earnings challenges.
Revenue increased 1.8% YoY to 15.0B yen, driven by the Medical segment which expanded 2.2% to 14.0B yen from 13.7B yen, while the Real Estate segment contracted 2.9% to 1.0B yen from 1.0B yen. Gross profit reached 6.7B yen with a margin of 44.4%, indicating strong pricing power and product mix. However, SG&A expenses of 7.3B yen exceeded gross profit, resulting in an operating loss of 0.6B yen compared to 0.4B yen loss in the prior year. The SG&A ratio of 48.3% against revenue highlights cost structure challenges, with unallocated corporate expenses increasing to 3.3B yen from 3.0B yen YoY according to segment notes. The deterioration accelerated at the ordinary income level, where non-operating expenses of 3.3B yen substantially impacted results. This non-operating burden primarily consisted of equity method losses of 3.1B yen from affiliates, representing a significant increase from the prior period. Extraordinary losses of 1.0B yen further pressured bottom-line results, though partially offset by 0.1B yen in asset sale gains. The gap between operating loss of 0.6B yen and net loss of 4.8B yen reflects the substantial impact of these non-recurring and equity method items, which contributed approximately 4.2B yen in additional losses. This represents a revenue up/profit down pattern, where modest top-line growth was overwhelmed by operating inefficiencies and substantial non-operating losses.
The Medical segment serves as the core business, generating 14.0B yen in revenue (93.3% of total) with operating income of 2.2B yen and a margin of 15.7%. This segment demonstrated resilience with 2.2% revenue growth YoY and improved segment profit from 2.1B yen to 2.2B yen. The Real Estate segment contributed 1.0B yen in revenue (6.7% of total) with operating income of 0.3B yen and a notably higher margin of 30.3%, though absolute profit declined from 0.4B yen to 0.3B yen YoY as revenue contracted from 1.0B yen. The margin differential of 14.6 percentage points between segments reflects the capital-light, rental-based nature of real estate operations versus medical services. Total segment profit of 2.5B yen was offset by unallocated corporate expenses of 3.1B yen (net of 0.02B yen inter-segment eliminations), resulting in consolidated operating loss of 0.6B yen. Corporate cost burden increased from 3.0B yen to 3.3B yen YoY, representing 21.7% of consolidated revenue and indicating significant overhead absorption challenges. The Medical segment's stable performance provides a foundation, but profitability is constrained by corporate cost structure and the small scale of higher-margin real estate operations.
[Profitability] ROE of -6.6% reflects substantial net losses against equity base of 73.4B yen, marking a significant deterioration from prior profitability levels. Operating margin of -3.8% compares unfavorably to the prior year, though gross margin of 44.4% demonstrates underlying business model strength. Net profit margin of -32.0% illustrates the severe impact of non-operating losses on overall profitability. [Cash Quality] Cash and deposits of 25.7B yen provide short-term debt coverage of 91.8x against long-term loans of 0.3B yen, indicating exceptional liquidity. Current assets of 46.0B yen against current liabilities of 5.2B yen yield a current ratio of 893.2%, substantially above standard safety thresholds. [Investment Efficiency] Asset turnover of 0.19 (revenue 15.0B yen / total assets 80.5B yen on annualized basis) reflects the asset-intensive nature of real estate holdings and medical facilities, with property, plant and equipment of 14.6B yen representing 18.1% of total assets. [Financial Health] Equity ratio of 91.1% positions the company in an exceptionally strong capital position with minimal leverage. Debt-to-equity ratio of 0.004 reflects negligible financial leverage with long-term loans of only 0.3B yen. The balance sheet contracted from 86.5B yen to 80.5B yen in total assets, primarily driven by retained earnings reduction of 5.0B yen (from 16.3B yen to 11.2B yen) due to accumulated losses.
Cash and deposits increased from 24.9B yen to 25.7B yen, maintaining robust liquidity despite operating losses, suggesting non-cash charges or working capital management contributed to cash preservation. Trade receivables of 1.6B yen represent approximately 10.7% of revenue, indicating efficient collection cycles. Trade payables decreased 27.5% from 3.2B yen to 2.3B yen, reflecting either accelerated payments to suppliers or reduced procurement volumes, which temporarily releases working capital but may indicate reduced operational scale or changed payment terms. The decline in total assets by 6.0B yen despite only modest revenue changes suggests potential asset disposals or impairments beyond the 0.1B yen gain on asset sales recorded as extraordinary income. Working capital remains exceptionally strong at 40.8B yen (current assets minus current liabilities), providing substantial operational cushion. The equity reduction from 78.4B yen to 73.4B yen primarily reflects the 4.8B yen net loss absorption, indicating internal capital consumption. With minimal debt service requirements (interest expense near zero) and substantial cash reserves, the company maintains financial flexibility despite earnings pressure.
Ordinary loss of 3.8B yen compared to operating loss of 0.6B yen reflects non-operating expenses of 3.3B yen, representing 21.7% of revenue and substantially degrading operating performance. The primary component is equity method losses of 3.1B yen from affiliated companies, indicating significant deterioration in investment portfolio performance. Other non-operating expenses of 0.1B yen and minimal interest expense suggest the burden is concentrated in equity method accounting rather than operational financial costs. Extraordinary losses of 1.0B yen partially offset by gains on asset sales of 0.1B yen represent non-recurring items equivalent to 6.0% of revenue, though the nature of these losses is not detailed. The substantial divergence between gross profit of 6.7B yen and net loss of 4.8B yen illustrates how non-operating factors, particularly the 3.1B yen equity method loss, overwhelm underlying business performance. Without cash flow statement data available for this quarterly period, the cash quality of earnings cannot be directly assessed, though the maintained cash position suggests non-cash charges may be significant components of reported losses. The concentration of losses in non-operating and extraordinary categories rather than core operations indicates earnings quality issues stem from investment portfolio performance rather than business model deterioration.
Full-year guidance projects revenue of 21.5B yen, operating income of 0.2B yen, and ordinary loss of 3.0B yen. Q3 cumulative progress rates stand at 69.9% for revenue, which lags the standard 75% seasonal benchmark by 5.1 percentage points, suggesting fourth quarter revenue acceleration is required to meet targets. Operating loss of 0.6B yen in Q3 cumulative versus full-year target of 0.2B yen profit indicates the company expects significant improvement, requiring approximately 0.8B yen swing to profitability in Q4 alone. The ordinary loss of 3.8B yen in Q3 has already exceeded the full-year ordinary loss guidance of 3.0B yen, indicating either guidance revision risk or expectation of substantial non-operating income recovery in Q4. The implied Q4 requirements appear challenging given current run rates. No forecast revision was announced this quarter despite ordinary loss exceeding full-year guidance, warranting close monitoring of Q4 execution and potential year-end guidance adjustment. The forecast assumes operating margin recovery and moderation of equity method losses, both representing key execution risks given YTD trends.
The company forecasts year-end dividend of 2.00 yen per share with no interim dividend, maintaining shareholder returns despite operating losses. Against forecasted EPS of -44.84 yen, the dividend represents a negative payout ratio, indicating dividends will be funded from retained earnings or cash reserves rather than current period earnings. Historical retained earnings of 11.2B yen provide capacity for dividend payments, though continued losses would pressure this capital cushion over time. With 9,051 thousand shares outstanding, total annual dividend commitment approximates 0.02B yen (18.1 million yen), representing a modest cash outflow relative to cash reserves of 25.7B yen. The maintenance of dividend payments during loss periods signals management confidence in business recovery and commitment to shareholder returns, though sustainability depends on return to profitability. No share buyback activity was disclosed for the current period. The total return ratio cannot be meaningfully calculated given negative earnings, though the absolute dividend commitment remains manageable given the strong balance sheet position.
Equity method investment portfolio performance poses the most significant risk, with 3.1B yen in losses during Q3 representing 20.6% of revenue and the primary driver of overall losses. Continued deterioration or failure of investee recovery would perpetuate losses and erode retained earnings, with limited disclosure on specific investee issues or recovery timelines constraining risk assessment. Operating cost structure inefficiency represents a structural profitability challenge, with SG&A expenses of 7.3B yen exceeding gross profit of 6.7B yen and corporate unallocated costs of 3.3B yen representing 21.7% of revenue. Without significant cost reduction or revenue scaling, operating profitability remains challenged even absent non-operating losses. Revenue growth deceleration risk emerges from the modest 1.8% YoY increase against industry median of 18.5%, with the Medical segment's 2.2% growth and Real Estate segment's 2.9% contraction suggesting limited organic expansion momentum. Market share loss or demand softness in core medical services could further pressure already negative operating margins.
[Industry Position] (Reference - Proprietary Analysis) The company's financial metrics show significant divergence from real estate industry medians based on Q3 2025 data. Profitability metrics fall substantially below industry standards: ROE of -6.6% compares unfavorably to industry median of 11.4% (IQR: 3.5%-20.6%, n=13), operating margin of -3.8% significantly trails the median of 8.0% (IQR: 2.8%-11.2%, n=13), and net profit margin of -32.0% contrasts sharply with median of 4.4% (IQR: 1.2%-7.2%, n=13). Revenue growth of 1.8% substantially lags the industry median of 18.5% (IQR: 6.9%-54.7%, n=13), positioning the company in the bottom quartile for top-line expansion. The equity ratio of 91.1% significantly exceeds industry median of 31.0% (IQR: 27.1%-45.8%, n=13), reflecting conservative capital structure with minimal leverage. Asset turnover of 0.19 falls well below industry median of 0.68 (IQR: 0.58-1.04, n=13), suggesting lower asset productivity potentially due to the medical segment composition. The current ratio of 893.2% far exceeds industry median of 2.15x (IQR: 1.94x-3.34x, n=13), indicating exceptional liquidity but potentially suboptimal capital deployment. ROIC comparison cannot be precisely assessed given negative operating returns. Overall positioning suggests a financially conservative company with strong balance sheet metrics but significant profitability and growth challenges relative to real estate industry peers. ※ Industry: Real Estate (13 companies), Comparison: 2025-Q3 period, Source: Proprietary analysis
The company demonstrates a bifurcated financial profile characterized by exceptional balance sheet strength with 91.1% equity ratio and 25.7B yen cash reserves, contrasted against severe profitability challenges driven primarily by non-operating factors rather than core business deterioration. The 44.4% gross margin indicates the underlying Medical and Real Estate businesses maintain pricing power, but structural operating losses emerge from SG&A expense burden of 48.3% of revenue, with unallocated corporate costs representing over 20% of revenue. The critical earnings quality observation centers on the 3.1B yen equity method loss representing 20.6% of revenue, which transformed modest operating losses into substantial net losses and suggests portfolio investment challenges require management attention and potential strategic review. Revenue growth of 1.8% significantly trails the industry median growth of 18.5%, indicating the company faces both profitability and growth headwinds relative to sector peers, though the stable Medical segment provides business continuity. The maintenance of dividend payments despite losses signals management confidence in recovery, supported by substantial financial cushion, though continued loss absorption would eventually pressure the retained earnings base that declined 30.8% from 16.3B yen to 11.2B yen during the period. The divergence between full-year ordinary loss guidance of 3.0B yen and Q3 cumulative actual of 3.8B yen ordinary loss represents a significant execution and forecast reliability concern requiring Q4 monitoring.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.